Promising avenue for treatment of ALS identified
News Aug 07, 2014
A series of studies begun by Harvard Stem Cell Institute (HSCI) scientists eight years ago has lead to a report published August 6 that may be a major step forward in the quest to develop real treatments for amyotrophic lateral sclerosis, ALS, or Lou Gehrig's disease.
The findings by Harvard professor of Stem Cell and Regenerative Biology (HSCRB) Kevin Eggan and colleagues have also produced functionally identical results in human motor neurons in a laboratory dish and in a mouse model of the disease, demonstrating that the modeling of human disease with customized stem cells in the laboratory could someday relatively soon eliminate some of the need for animal testing.
The new study, published August 6 in Science Translational Medicine, suggest that compounds already in clinical trials for other purposes may be promising candidate therapeutics for ALS. The Harvard authors found that genetically intervening in the pathway these drugs act on increased survival time of an ALS animal model 5-10 percent, and while that is a long way from curing the universally fatal neurodegenerative disease, "any ALS patient would be excited about this extended life span," said Eggan, who pioneered the disease in a dish concept.
Sophie De Boer, a graduate student in Eggan's lab, is the first author on the Science Translational Medicine paper.
This latest finding is expected to push towards clinical studies the second major ALS discovery from Eggan's lab in less than a year. The HSCI stem cell biologist, and his neuroscience and neurology collaborators at Massachusetts General Hospital and Boston Children's Hospital, are preparing for a phase I clinical trial of a medication already approved for epilepsy which Eggan and colleagues discovered quiets disease related electrical excitability in the motor neurons effected in ALS.
In a paper in 2007, Eggan and colleagues demonstrated that glial cells, background cells in the nervous system, were involved in motor neuron degeneration in a mouse model of ALS. And the following year the researchers reported that the same thing was happening in human motor neurons made from patient stem cells, and proposed that prostanoid molecules, a group of substances involved in inflammation in everything from pain to pregnancy, might be playing a role in the glial cells.
Today the researchers reported they have confirmed there is a change in prostanoid receptors in the gial cells playing a role in ALS, and with genetic and chemical experiments they showed that this is playing a role in ALS. They further report that when the effected receptor is blocked, the ALS damage done by the glial cells is reduced.
This latest work, notes Eggan, first done in human motor neurons in a dish, and then in a mouse model of ALS, "says that indeed this stem cell model was predictive of something that can happen inside a whole animal, and is important because it demonstrates that this is really an important target for an ALS therapeutic. If we can inhibit this receptor in an ALS patient, we might slow down the progression of the disease, and that would be a huge step."
"One feature of the glial cells in ALS that attack motor neurons is that they have higher expression of this prostanoid receptor. Removing just one of the two copies of the receptor in the glial cells had an effect on extending the life span of the ALS mice," Eggan said, and "inhibition by a drug is unlikely to have an effect as complete as a knockout in the mice."
Eggan indicates that experiments on human stem cell-generated ALS motor neurons also show that "if we inhibit that receptor in the ALS cells with a chemical, those cells lose their toxicity to motor neurons. This is a very exciting period for those whose lives are threatened by ALS, and it is exciting for my lab. First we recently identified a pathway that we think is important for degeneration inside the motor neuron, and now we've found this pathway in cells outside the motor neuron. This has potential to have a very substantial effect on what's happening in ALS."
Note: Material may have been edited for length and content. For further information, please contact the cited source.
A. S. de Boer, K. Koszka, E. Kiskinis, N. Suzuki, B. N. Davis-Dusenbery, K. Eggan. Genetic validation of a therapeutic target in a mouse model of ALS. Science Translational Medicine, Published August 6 2014. doi: 10.1126/scitranslmed.3009351